Transgene – L'immunothérapie contre les cancers

R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

TRANSGENE R&D DAY

Transgene Confirms the Potential of the Intravenous Route
of its Invir.IO™ Oncolytic Viruses against Solid Tumors
with TG6002 Phase I Data Presented at ESMO Congress 2022

2Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®

Transgene and bioinvent announce clinical collaboration

Transgene and BioInvent announce positive progress for BT-001

Transgene presented additional Phase I Data with TG4050 at ASCO 2022

Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF

JB Marchand et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors

Semmrich M, Marchand J, Fend L, et alJournal for ImmunoTherapy of Cancer Download the publication herePublication

Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors

Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform

Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

20211109 – Transgene BioInvent SITC BT-001 en

Cookie	Duration	Description
__cfduid	1 month	The cookie is used by cdn services like CloudFare to identify individual clients behind a shared IP address and apply security settings on a per-client basis. It does not correspond to any user ID in the web application and does not store any personally identifiable information.
viewed_cookie_policy	1 year	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	1 year	This cookie is used to distinguish users on your website. It calculates visitor, session, and campaign data and keeps track of site usage for the site’s analytics report.
_gat_gtag_UA_158044571_1	1 minute	Used to persist session state. More information: https://developers.google.com/analytics/devguides/collection/gtagjs/cookie-usage
_gid	1 day	This cookie is used to distinguish users on your website. It is used to store information on how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected includes the number of visitors, their source, and the pages visited.
vuid	1 year	This domain of this cookie is owned by Vimeo. This cookie is used by vimeo to collect tracking information. It sets a unique ID to embed videos to the website.

menu secondaire

Category: Invir.IO